Henan Taloph Pharmaceutical Stock Co.,Ltd (SHA:600222)

Market Cap	3.75B
Revenue (ttm)	1.79B
Net Income (ttm)	46.95M
Shares Out	552.92M
EPS (ttm)	0.08
PE Ratio	80.05
Forward PE	n/a
Dividend	0.03 (0.41%)
Ex-Dividend Date	n/a

Volume	20,455,600
Average Volume	43,696,169
Open	6.95
Previous Close	6.94
Day's Range	6.79 - 6.95
52-Week Range	4.51 - 9.44
Beta	0.82
RSI	43.13
Earnings Date	Apr 15, 2026

About SHA:600222

Henan Taloph Pharmaceutical Stock Co.,Ltd engages in the research, development, and sale of pharmaceutical preparations and Chinese herbal medicines in China. Its principal products include Shuanghuanglian oral liquid series, Shuangjinlian mixture, pediatric Qingrezhike oral liquid, Huoxiangzhengqi mixture, Danshen and Wuzi Yanzong oral liquid, Shengmaiyin, pediatric compound chicken gizzard chewable tablets, Huperzine A tablets, compound Yimu oral liquid. The company serves hospitals, primary medical institutions, and retail terminals. Henan T...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1993
• Employees: 2,214
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600222

Financial Performance

In 2024, SHA:600222's revenue was 1.94 billion, a decrease of -6.21% compared to the previous year's 2.07 billion. Earnings were 50.53 million, an increase of 16.00%.